MK3475-199-05: Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)

February 18, 2019
https://clinicaltrials.gov/ct2/results?id=NCT02787005
Cancer - Prostate, Cancer - Bladder
Principal Investigator: Clara Hwang, MD
Cancer, Prostate Cancer, Phase 2, Phase II, Castration-resistant prostate cancer, pembrolizumab
Open